This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
cancer: Archive
Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings
by Sundeep Ganoria
Investors will likely focus on the sales performance of Jazz Pharmaceuticals' key neuroscience drugs, Xywav and Rylaze, when it reports Q1 results next week.
JAZZPositive Net Change AMRXNo Net Change
biotechs cancer cannabis earnings-preview marijuana medical
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?
by Ekta Bagri
At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV prevention, and recent positive estimate revisions.
BMYNegative Net Change MRKPositive Net Change GILDPositive Net Change
biotechnology biotechs cancer cell-therapy medical pharmaceuticals
Top Cancer Stocks to Buy to Boost Your Portfolio's Health
by Kinjel Shah
If the cancer space appeals to you, it's time to consider stocks like Pyxis Oncology, Verastem Oncology and Relay Therapeutics.
AZNNegative Net Change NVSPositive Net Change PFENegative Net Change ABBVPositive Net Change VSTMNegative Net Change RLAYNegative Net Change PYXSPositive Net Change
cancer
Tap Into the Silver Economy Boom With These Aging Demographics Stocks
by Urmimala Biswas
The global demographic shift is reshaping healthcare demand, driving long-term investment in pharmaceuticals, medical devices, home care and digital health.
ABTNegative Net Change NVOPositive Net Change RMDNegative Net Change DXCMPositive Net Change TNDMNegative Net Change
cancer healthcare hospitals medical medical-devices oncology-screening pharmaceuticals thematic
Recursion Pharma Down 37% in a Month: Buy, Sell or Hold the Stock?
by Ahan Chakraborty
Despite the current downward trend of RXRX, one should retain the stock for long-term gains due to the significant potential of its AI-driven drug discovery technology.
RHHBYPositive Net Change MRKPositive Net Change BAYRYNegative Net Change RXRXNegative Net Change
artificial-intelligence biotechnology biotechs cancer medical oncology-screening pharmaceuticals
Follow the Leader: 2 Biopharma Stocks Showing Relative Strength in 2025
by Bryan Hayes
Despite a correction to begin the year, there are a few pockets of the market that are working.
GILDPositive Net Change JAZZPositive Net Change
biotechnology biotechs cancer cell-therapy earnings immuno-therapy investing medical oncology-screening pharmaceuticals
Pharmaceutical Stocks Hit New Highs Amid Market Volatility
by Bryan Hayes
During this time of heightened market volatility, it pays to be invested in the right places.
GILDPositive Net Change
cancer cell-therapy coronavirus earnings immuno-therapy investing medical oncology-screening vaccines
Hologic Trades at 17.62X P/E: Should You Buy, Sell or Hold the Stock?
by Moumi Mondal
Despite the current challenges, HOLX's portfolio strength and international growth prospects make it worth holding on to.
MASIPositive Net Change GMEDPositive Net Change
cancer medical medical-devices
Should You Bet on HOLX Stock This Breast Cancer Awareness Month?
by Moumi Mondal
Hologic has kicked off the annual breast cancer awareness month with a new campaign. But how well is the stock doing now?
ABTNegative Net Change QGENPositive Net Change
cancer medical medical-devices
Why Biotech ETFs Are Beating the Market
by Neena Mishra
: Biotech stocks are poised to benefit from lower rates
REGNNegative Net Change GILDPositive Net Change IBBNegative Net Change XBINegative Net Change SBIONegative Net Change
biotechnology biotechs cancer cell-therapy etfs